Lv1
68 积分 2024-02-05 加入
Guidelines for the management of hereditary ATTR amyloidosis 2026
13天前
已完结
Lp(a) in chronic kidney disease: state of the art and management perspectives
13天前
已完结
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
23天前
已完结
Asundexian for Secondary Stroke Prevention
1个月前
已完结
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
1个月前
已完结
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
1个月前
已完结
Evidence‐Based Recommendations on the Use of Inclisiran in Patients With Chronic Kidney Disease
3个月前
已完结
Recent developments in pharmacophore-based modeling of Ca 2+/ Calmodulin-dependent protein kinase II delta (CaMkIIδ) inhibitors for heart failure therapy
3个月前
已完结
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial
4个月前
已完结
皖公网安备34019202002308
